Prevalence of metabolic syndrome among an iranian cohort of inpatients with schizophrenia

International Journal of Psychiatry in Medicine

Volumn 39, Issue 4, 2009, Pages 451-462

  Rezaei, Omid ^a   Khodaie Ardakani, Mohammad Reza ^a   Mandegar, Mohammad Hossein ^b   Dogmehchi, Ensyeh ^b   Goodarzynejad, Hamidreza ^b  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Metabolic syndrome; Obesity; Schizophrenia

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HEALTH; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SURVEYS; HOSPITALIZATION; HUMANS; IRAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA;

EID: 76949090544     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.39.4.i     Document Type: Article

References (33)

1. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Science 2002;71(3):239-257.
2. Brown S. Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 1997;171:502-508.
3. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000;177:212-217.
4. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in StockholmCounty, Sweden. Schizophrenia Research 2000; 45(1-2):21-28.
5. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24(4):683-689.
6. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41(6):715-722.
7. Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Journal of Clinical Psychiatry 2004;65(5):715-720.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001;285(19):2486-2497.
9. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Arteriosclerosis and Thrombic Vascular Biology 2004;24(2):e13-e18.
10. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-A new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetes Medicine 2006;5(3):80-469.
11. Misra A, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition 2005;21(9):969-976.
12. Kraja AT, Rao DC, Weder AB, Mosley TH, Turner ST, Hsiung CA, et al. An evaluation of the metabolic syndrome in a large multi-ethnic study: The Family Blood Pressure Program. Nutrition and Metabolism (London) 2005;2:17.
13. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 2006;83(1):87-93.
14. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry 2004;49(11):753-760.
15. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005;80(1):19-32.
16. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy, and research challenges. Journal of Clinical Psychiatry 2008; 69(4):514-519.
17. De Hert, Schreurs V, Vancampfort D, Van Winkel, R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 2009;8(1):15-22.
18. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatrica Scandinavica 2009;119(1):4-14.
19. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Research Clinical Practice 2003;61(1):29-37.
20. De Nayer A, De Hert, M, Scheen A, Van Gaal L, Peuskens J. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. International Journal of Psychiatry in Clinical Practice 2005;9(2):130-137.
21. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 2004;161(8):1334-1349.
22. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder- Bipolar subtype. Bipolar Disorders 2004;6(4):314-318.
23. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry 2003;64(5):575-579.
24. De Hert M, Falissard B, Mauri M, Shaw K, Wetterling T. P03-135 Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The meteor study. European Psychiatry 2009;24(Suppl 1):S1134.
25. Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, et al. Characteristics of diabetes mellitus in schizophrenic patients. Journal of the Medical Association of Thailand 1987;70(Suppl 2):90-93.
26. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry 1996;37(1):68-73.
27. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 2000;26(4):903-912.
28. Taylor D, Young C, Mahomed R, Paton C. P.2.099 A prevalence study of impaired glucose tolerance and diabetes mellitus in hospitalized patients with schizophrenia. European Neuropsychopharmacology 2003;13(Suppl 4):S323.
29. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Canadian Journal of Psychiatry 2003;48(5):345-347.
30. Rouillon F, Sorbara F. Schizophrenia and diabetes: Epidemiological data. European Psychiatry 2005;20(Suppl 4):S345-S348.
31. Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. European Neuropsychopharmacology 2006;16(3):187-194.
32. Amini M, Afshin-Nia F, Bashardoost N, Aminorroaya A, Shahparian M, Kazemi M. Prevalence and risk factors of diabetes mellitus in the Isfahan city population (aged 40 or over) in 1993. Diabetes Research and Clinical Practice 1997;38(3):185-190.
33. Casadebaig F, Philippe A, Guillaud-Bataille JM, Gausset MF, Quemada N, Terra JL. Schizophrenic patients: Physical health and access to somatic care. European Psychiatry 1997;12(6):289-293.